Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 13/20 | 0.85 |
| ▸ | PRMT6 | Q96LA8 | 13/20 | 0.85 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD5 | P21918 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788490 | 0.83 | CARM1 (0.60) | CARM1PRMT6DRD2DRD1DRD4 | |
| SCHEMBL8476000 | 0.83 | CARM1 (0.82) | CARM1PRMT6DRD2KMT2ASIGMAR1 | |
| SCHEMBL1546828 | 0.81 | DRD2 (0.83) | CARM1PRMT6DRD2DRD1DRD4 | |
| SCHEMBL1546830 | 0.81 | DRD2 (0.83) | CARM1PRMT6DRD2DRD1DRD4 | |
| SCHEMBL7059983 | 0.79 | ALDH1A1 (0.58) | CARM1PRMT6DRD2DRD1DRD4 | |
| SCHEMBL25946287 | 0.79 | DRD2 (0.69) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL25366560 | 0.78 | SLC18A3 (0.83) | CARM1PRMT6DRD2DRD1DRD4 | |
| SCHEMBL19493848 | 0.78 | SLC18A3 (0.83) | CARM1PRMT6DRD2DRD1DRD4 | |
| SCHEMBL14813507 | 0.78 | KMT2A (0.57) | CARM1PRMT6DRD2DRD1DRD4 | |
| SCHEMBL22307922 | 0.78 | DRD2 (0.66) | CARM1PRMT6DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2014210159-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | CFTR, HSP90B1, SERPINB1 | CARM1 4418/4885PRMT6 3099/4885DRD2 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.